- Won a denial of class certification for a health care company and pharmacy benefit manager facing claims involving manufacturer rebates and prescription drug prices.
- Counsel for an international consulting firm in a noncompetition, nonsolicitation, and trade secret case that settled favorably prior to jury selection.
- Counsel to a national insurance company defending against a putative class action involving interest payments.
- Assisted an international financial institution with an internal investigation into misuse of company assets.
- Represented a Fortune 50 plaintiff in litigation involving trade secrets and negotiations with the employee union.
- Counsel for a professional sports franchise in a stadium safety case that settled favorably prior to trial.
- Pro bono defense counsel to a nonprofit housing provider facing a breach of contract claim.
Senior Associate,
- Phone: +1 404 881 7829
- Email: bradley.harder@alston.com
Brad applies his experience in the federal judiciary and a state law department to accomplish clients’ goals in litigation, investigations, and commercial disputes.
Bradley Harder is a senior associate in Alston & Bird’s Litigation & Trial Practice Group with experience in health care litigation, class actions, government investigations, and other complex commercial litigation. He handles all phases of litigation on behalf of clients from many sectors, including insurance, finance, and health care.
Brad serves on the board of Mental Health America of Georgia, and he maintains an active pro bono practice in collaboration with Kids in Need of Defense. In 2023–2025, The Best Lawyers in America® recognized Brad as “One to Watch” in its list of lawyers who have demonstrated outstanding professional excellence early in their careers.
Before joining Alston & Bird, Brad worked as a Georgia assistant attorney general representing state agencies and employees, and he clerked for the Honorable Louise W. Flanagan of the U.S. District Court for the Eastern District of North Carolina.
Brad graduated with honors as a Chancellors Scholar from the University of North Carolina School of Law, where he served as an editor on the North Carolina Law Review and as a judicial extern for the Honorable Joe L. Webster of the U.S. District Court for the Middle District of North Carolina. He earned his undergraduate degree with high honors with a full merit scholarship at Washington and Lee University.
-
Class Action MDL Roundup March 26, 2025Class Action & MDL Roundup 2024 Q4 – We give you the benefit of the bargainIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the fourth quarter of 2024, an overdue audiobook suit is shelved, an old case gets new reps and new evidence, and face-swappers get SLAPPed. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup March 26, 2025Class Action & MDL Roundup 2024 Q4 – We give you the benefit of the bargainIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the fourth quarter of 2024, an overdue audiobook suit is shelved, an old case gets new reps and new evidence, and face-swappers get SLAPPed. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup January 3, 2025Class Action & MDL Roundup 2024 Q3 – Our market research is sustainableIn this edition, it’s not a breach if it isn’t stolen, a greenwashing claim is washed away, and a district court’s denial swims with the fishes. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup January 3, 2025Class Action & MDL Roundup 2024 Q3 – Our market research is sustainableIn this edition, it’s not a breach if it isn’t stolen, a greenwashing claim is washed away, and a district court’s denial swims with the fishes. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup October 2, 2024Class Action & MDL Roundup 2024 Q2 – We are administratively feasibleIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the second quarter of 2024, there can be only one claim form for many, broiler chickens are coming home to roost, and there is no conspiracy of memes. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup October 2, 2024Class Action & MDL Roundup 2024 Q2 – We are administratively feasibleIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the second quarter of 2024, there can be only one claim form for many, broiler chickens are coming home to roost, and there is no conspiracy of memes. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup July 2, 2024Class Action & MDL Roundup 2024 Q1 – Reaching across the pondIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the first quarter of 2024, UK High Court weighs in on information asymmetry, debit is better than credit, and it helps to have a credible plaintiff. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup July 2, 2024Class Action & MDL Roundup 2024 Q1 – Reaching across the pondIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the first quarter of 2024, UK High Court weighs in on information asymmetry, debit is better than credit, and it helps to have a credible plaintiff. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup March 21, 2024Class Action & MDL Roundup 2023 Q4 - Not all cases survive and advance
In this edition, student-athletes win an NIL round, Canadians in California isn’t personal (jurisdiction), and it’s only a duty to disclose when it’s material. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
Class Action MDL Roundup March 21, 2024Class Action & MDL Roundup 2023 Q4 - Not all cases survive and advanceIn this edition, student-athletes win an NIL round, Canadians in California isn’t personal (jurisdiction), and it’s only a duty to disclose when it’s material. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup December 18, 2023Class Action & MDL Roundup 2023 Q3 - Catching the class action waive(r)In the latest edition of the Class Action & MDL Roundup, covering notable class actions from the third quarter of 2023, a mistake is just a mistake, “99.99%” isn’t 100% clear, and faxes aren’t always free. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup December 18, 2023Class Action & MDL Roundup 2023 Q3 - Catching the class action waive(r)In the latest edition of the Class Action & MDL Roundup, covering notable class actions from the third quarter of 2023, a mistake is just a mistake, “99.99%” isn’t 100% clear, and faxes aren’t always free. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup September 29, 2023Class Action & MDL Roundup 2023 Q2 – Ascertainability lives!In the latest edition of the Class Action & MDL Roundup, covering notable class actions from the second quarter of 2023, essential oils may need therapy, an ever-growing library goes nowhere, and one exclusion is specifically ambiguous. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup September 29, 2023Class Action & MDL Roundup 2023 Q2 – Ascertainability lives!In the latest edition of the Class Action & MDL Roundup, covering notable class actions from the second quarter of 2023, essential oils may need therapy, an ever-growing library goes nowhere, and one exclusion is specifically ambiguous. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup June 30, 2023Class Action & MDL Roundup 2023 Q1 – We don’t discount confidentialityIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the first quarter of 2023, in pork we antitrust, paid time off is not pay, and if it’s free, it won’t cost you a TCPA violation. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup June 30, 2023Class Action & MDL Roundup 2023 Q1 – We don’t discount confidentialityIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the first quarter of 2023, in pork we antitrust, paid time off is not pay, and if it’s free, it won’t cost you a TCPA violation. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup March 27, 2023Class Action & MDL Roundup 2022 Q4 – A “healthy” dose of litigationIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the fourth quarter of 2022, class actions gain an international flair, insurers have cures for COVID cases, and a remote presence is still a presence. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup March 27, 2023Class Action & MDL Roundup 2022 Q4 – A “healthy” dose of litigationIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the fourth quarter of 2022, class actions gain an international flair, insurers have cures for COVID cases, and a remote presence is still a presence. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup December 20, 2022Class Action & MDL Roundup 2022 Q3 – The very definition of all naturalIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the third quarter of 2022, all dog stairs go to heaven, the Third Circuit resets Article III standing, and challenging damages can be aggregating. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup December 20, 2022Class Action & MDL Roundup 2022 Q3 – The very definition of all naturalIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the third quarter of 2022, all dog stairs go to heaven, the Third Circuit resets Article III standing, and challenging damages can be aggregating. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
Bar Admissions
- Georgia
Education
- University of North Carolina (J.D., 2015)
- Washington and Lee University (B.A., 2012)